Status: Recruiting
NALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer
This study aims to evaluate the safety and preliminary efficacy of NALIRIFOX combined with adebrelimab and PULSAR as first-line treatment for locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC). Additionally, it will explore potential predictive and efficacy-related biomarkers.
Participants needed: 55
Trial details
Phase: Phase 1, Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: West China HospitalUpdated: May 19, 2026Locations: 1
Eligibility criteria
Age: 18-75 years, regardless of gender. [+9]
History of severe hypersensitivity to chimeric, human(ized) antibodies, or fusio... [+15]